Interpret the correct usage and dosage of eltrombopag

Eltrombopag Belongs to a class of drugs called thrombopoietin receptor agonists, which work by causing bone marrow cells to produce more platelets. Eltrombopag is suitable for patients with persistent or chronic immune thrombocytopenia(ITP), thrombocytopenia in patients with chronic hepatitis C, and severe aplastic anemia. How to dose eltrombopag?

Eltrombopag is administered orally as tablets or oral suspension at the lowest dose necessary to achieve and maintain platelet counts ≥50,000/mm3 necessary to reduce bleeding risk or maintain hematologic response. Eltrombopag is taken without or with meals and has a low calcium content(≤50 mg). Calcium-containing foods and medications may reduce the rate and extent of eltrombopag's absorption; therefore, it is not recommended to take other medications(such as antacids) , calcium-rich foods(such as dairy products, and certain fruits and vegetables span>)or take at least 2 hours before or after supplements containing polyvalent cations(such as iron, calcium, aluminum, magnesium, selenium, zinc). If possible, consider dosing in the evening (unless the patient is also taking an antacid containing polyvalent cations) because calcium-containing foods (such as dairy products) are more often consumed with breakfast.

The patient labeling for persistent or chronic immune thrombocytopenia (ITP) recommends a starting dose of 25 mg once daily to a maximum dose of 75 mg. Under normal circumstances, the platelet count will increase within 1-2 weeks of taking this product. According to the clinical platelet count, the dose of this product should be adjusted to maintain the normal range of platelet count. For chronic hepatitis Cpatients, the starting dose is 25mg once daily, then increasing by 25mg every two weeks until normal platelet counts are achieved, to a maximum daily dose of 100mg. For patients with severe aplastic anemia,12The starting dose for patients years and above is 150mg once a day for 6 months. The starting dose for pediatric patients 6-11 years old is 75mg once a day for 6 months. The starting dose for pediatric patients aged 2-5 is 2.5mg/kg once a day for 6 months.

Risk of hepatic decompensation in patients with chronic hepatitis C:In patients with chronic hepatitis C, eltrombopag combined with interferon and ribavirin may increase the risk of hepatic decompensation. Risk of hepatotoxicity:This drug may increase the risk of serious and potentially life-threatening hepatotoxicity. Monitor liver function and discontinue dosing as recommended. Safety and efficacy have not been established in patients younger than 1 year old with ITP. The safety and effectiveness of the combination of equine antithymocyte globulin (h-ATG) and cyclosporine in the first-line treatment of patients younger than 2 years old with severe aplastic anemia has not been established. Safety and efficacy have not been established in patients <18 years of age with chronic hepatitis C and severe aplastic anemia-associated thrombocytopenia. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0